NATURAL PRODUCT RESEARCH AND DEVELOPMENT ›› 2023, Vol. 35 ›› Issue (8): 1348-1356.doi: 10.16333/j.1001-6880.2023.8.007

Previous Articles     Next Articles

Isolation and antitumor activity of phenylspirodrimane derivatives from the fungus Stachybotrys sp. CPCC 401591

RONG Xiao-ting1,2,HE Wen-ni1,GUO Zhe1,LI Xin-xin1,WANG Lu1,GAO Kun2,YU Li-yan1*,ZHANG Tao1*   

  1. 1Institute of Medicinal Biotechnology,Chinese Academy of Medical Sciences & Peking Union Medical College,Beijing 100050,China;2College of Biotechnology,Jiangsu University of Science and Technology,Zhenjiang 212100,China
  • Online:2023-08-28 Published:2023-08-30

Abstract:

The phenylspirodrimane derivatives exhibiting antitumor bioactivities were isolated from the fermentation crude extract of the fungal strain Stachybotrys sp.CPCC 401591.In the study,OSMAC (one strain many compounds) approach was conducted to optimize the fermentation medium.LC-MS/MS-based molecular network analysis was performed for guiding isolation process of secondary metabolites.The routine separation approaches for purification included ethyl acetate extraction,sillica gel column chromatography and preparative HPLC.Eight compounds were obtained and their structures were elucidated as chartarlactam H (1),chartarlactam F (2),stachybotrin (3),chartarlactam K (4),stachybotrylactam (5),F1839-A (6),Mer-VGF724B (7),and 3α-hydroxy-N-isopropyl-carboxyl -phenylspirodrimane (8) by analysis of spectroscopic data including nuclear magnetic resonance,mass spectrometry analysis,and Mo2(OAc)4-induced circular dichroism (CD) spectra.The cytotoxic activity of the compounds 1-8 were evaluated by CCK-8 assay in vitro.The results showed that compounds 1-8 displayed moderate inhibition activities on human hepatoma carcinoma cells HepG2,human cervical cancer cells HeLa,and human colon cancer cells HCT116.The result could provide scientific basis for mining more new antitumor compounds from Stachybotrys genus.

Key words: Stachybotrys, global natural products social molecular networking, phenylspirodrimanes, antitumor

CLC Number: